Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.

Jeffery Taubenberger, the acting head of the NIAID, the NIH’s infectious disease institute, is reported to have stepped down.

In response to an Ebola outbreak, the U.S. has banned entry for noncitizens who have been in the Democratic Republic of the ...

After a quick break, I’ll bring you our conversation about perimenopause, menopause, and what happens when women are seen as ...

Amid another Ebola outbreak, hundreds of Africans are sick, displaced, fearful, or dead. Health care workers across Central ...

With no approved vaccine for the fast-growing Ebola outbreak in the DRC, experts weigh testing one with unknown protection.

My patients are replacing olive oil with beef tallow, even if they don't tell me during cardiac rehab,” writes a clinical ...

President Trump's cuts to foreign aid probably hampered the detection of the Ebola outbreak and the response to it.

Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The ...

Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the ...

An NIH leadership vacuum has persisted for months, with 15 of the 27 institutes being led by acting directors.

The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable showdown with ...